Good Distribution Practices (GDP) Services
Pharmaceutical distribution involves continuous risk exposure — during storage, transportation, handling, and transfer between supply chain partners. Maintaining product identity, traceability, and environmental control is essential to ensure patient safety and regulatory compliance.
GXPWAY provides end-to-end Good Distribution Practice (GDP) support to establish, implement, and maintain compliant pharmaceutical distribution systems across local and international supply networks.
Distribution Compliance Frameworks
We help organisations design distribution systems that protect medicinal product integrity from receipt to final delivery.
Distribution Quality System Implementation
GDP-aligned operational procedures
Controlled product handling protocols
Documentation and record-keeping systems
Traceability and batch tracking structures
Responsible Person (RP) Support
RP advisory and operational guidance
Oversight structure development
Regulatory responsibility mapping
Ongoing compliance supervision
Supply Chain Risk Control
Risk assessment of transport routes and logistics partners
Environmental exposure control strategies
Incident management and reporting frameworks
Product recall and complaint handling systems
Temperature and Cold Chain Management
Temperature control requirements definition
Monitoring system selection and validation
Excursion management procedures
Transport qualification and environmental verification
Vendor and Logistics Partner Qualification
Third-party GDP assessments
Service provider performance monitoring
Quality agreements and compliance obligations
Operational Integration
Our approach ensures that GDP requirements are embedded into real operational workflows — not maintained as standalone documentation. This creates consistent, verifiable control across the entire distribution process.
Outcomes for Your Organisation
Secure and compliant distribution network
Full product traceability across supply chain stages
Controlled temperature and environmental handling
Reduced risk of product compromise or regulatory findings
Demonstrable GDP compliance during inspections
